217 related articles for article (PubMed ID: 38512540)
21. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
22. Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study.
Bailey TS; Zhou FL; Gupta RA; Preblick R; Gupta VE; Berhanu P; Blonde L
Diabetes Obes Metab; 2019 Jul; 21(7):1596-1605. PubMed ID: 30843339
[TBL] [Abstract][Full Text] [Related]
23. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
Owens DR; Traylor L; Mullins P; Landgraf W
Diabetes Res Clin Pract; 2017 Feb; 124():57-65. PubMed ID: 28092788
[TBL] [Abstract][Full Text] [Related]
24. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
25. Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of Older Patients With Type 2 Diabetes Mellitus.
Pratley RE; Rosenstock J; Heller SR; Sinclair A; Heine RJ; Kiljański J; Brusko CS; Duan R; Festa A
J Diabetes Sci Technol; 2018 Nov; 12(6):1184-1191. PubMed ID: 29893144
[TBL] [Abstract][Full Text] [Related]
26. Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: A retrospective real world comparative data from India.
Ghosal S; Sinha B; Gangopadhyay KK
Diabetes Metab Syndr; 2016; 10(3):161-5. PubMed ID: 26822462
[TBL] [Abstract][Full Text] [Related]
27. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB; Botros FT
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):605-617. PubMed ID: 29910024
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures.
Lingvay I; Chao J; Dalal MR; Meneghini LF
Diabetes Technol Ther; 2017 May; 19(5):315-322. PubMed ID: 28467113
[TBL] [Abstract][Full Text] [Related]
29. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
Pan C; Gross JL; Yang W; Lv X; Sun L; Hansen CT; Xu H; Wagner R
Drugs R D; 2016 Jun; 16(2):239-49. PubMed ID: 27098525
[TBL] [Abstract][Full Text] [Related]
30. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.
Bolli GB; Riddle MC; Bergenstal RM; Wardecki M; Goyeau H; Home PD;
Diabetes Metab; 2017 Sep; 43(4):351-358. PubMed ID: 28622950
[TBL] [Abstract][Full Text] [Related]
31. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis.
Díez-Fernández A; Cavero-Redondo I; Moreno-Fernández J; Pozuelo-Carrascosa DP; Garrido-Miguel M; Martínez-Vizcaíno V
Acta Diabetol; 2019 Mar; 56(3):355-364. PubMed ID: 30506484
[TBL] [Abstract][Full Text] [Related]
33. New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.
Goldman J; White JR
Ann Pharmacother; 2015 Oct; 49(10):1153-61. PubMed ID: 26238470
[TBL] [Abstract][Full Text] [Related]
34. Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo
Wiesli P; Schories M
Diabetes Ther; 2018 Dec; 9(6):2325-2334. PubMed ID: 30302721
[TBL] [Abstract][Full Text] [Related]
35. Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study.
Malik RA; Hwu CM; Jammah AA; Arteaga-Díaz JM; Djaballah K; Pilorget V; Alvarez A; Vera C; Vikulova O
Diabetes Obes Metab; 2024 Jul; 26(7):2811-2819. PubMed ID: 38637981
[TBL] [Abstract][Full Text] [Related]
36. More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
Rosenstock J; Cheng A; Ritzel R; Bosnyak Z; Devisme C; Cali AMG; Sieber J; Stella P; Wang X; Frías JP; Roussel R; Bolli GB
Diabetes Care; 2018 Oct; 41(10):2147-2154. PubMed ID: 30104294
[TBL] [Abstract][Full Text] [Related]
37. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
[TBL] [Abstract][Full Text] [Related]
39. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
Home PD; Bergenstal RM; Bolli GB; Ziemen M; Rojeski M; Espinasse M; Riddle MC
Diabetes Care; 2015 Dec; 38(12):2217-25. PubMed ID: 26084341
[TBL] [Abstract][Full Text] [Related]
40. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
Xie L; Wei W; Pan C; Baser O
J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
